227 related articles for article (PubMed ID: 38151740)
1. An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapy.
Lumry WR; Bernstein JA; Li HH; Levy DS; Jones DH; Padilla BE; Li-Mcleod J; Tachdjian R
Allergy Asthma Proc; 2024 Jan; 45(1):44-49. PubMed ID: 38151740
[No Abstract] [Full Text] [Related]
2. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.
Manning ME; Kashkin JM
Allergy Asthma Proc; 2021 Jul; 42(4):274-282. PubMed ID: 34127176
[No Abstract] [Full Text] [Related]
3. Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
[TBL] [Abstract][Full Text] [Related]
4. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
Ohsawa I; Honda D; Suzuki Y; Fukuda T; Kohga K; Morita E; Moriwaki S; Ishikawa O; Sasaki Y; Tago M; Chittick G; Cornpropst M; Murray SC; Dobo SM; Nagy E; Van Dyke S; Reese L; Best JM; Iocca H; Collis P; Sheridan WP; Hide M
Allergy; 2021 Jun; 76(6):1789-1799. PubMed ID: 33247955
[TBL] [Abstract][Full Text] [Related]
5. A review of berotralstat for the treatment of hereditary angioedema.
Farkas H; Balla Z
Expert Rev Clin Immunol; 2023 Feb; 19(2):145-153. PubMed ID: 36408587
[TBL] [Abstract][Full Text] [Related]
6. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.
Gower RG; Lumry WR; Davis-Lorton MA; Johnston DT; Busse PJ
Allergy Asthma Proc; 2012; 33(3):235-40. PubMed ID: 22584192
[TBL] [Abstract][Full Text] [Related]
7. Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat.
Riedl MA; Soteres D; Sublett JW; Desai B; Tomita D; Collis P; Bernstein JA;
Ann Allergy Asthma Immunol; 2024 Apr; 132(4):505-511.e1. PubMed ID: 38006972
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological and clinical study results of Berotralstat Hydrochloride for long-term prophylactic treatment of hereditary angioedema].
Orui S; Nozue H; Kobayashi S; Fujioka M; Maekawa Y
Nihon Yakurigaku Zasshi; 2021; 156(6):382-390. PubMed ID: 34719573
[TBL] [Abstract][Full Text] [Related]
9. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.
Kiani-Alikhan S; Gower R; Craig T; Wedner HJ; Kinaciyan T; Aygören-Pürsün E; Banerji A; Bernstein JA; Anderson J; Collis P; Johnston DT; Desai B; Tomita D; Gagnon R; Tachdjian R; Soteres DF; Farkas H; Caballero T; McNeil D; Jacobs J; Lumry WR;
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):733-743.e10. PubMed ID: 38122865
[TBL] [Abstract][Full Text] [Related]
10. Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema.
Powell J; Piszczatoski C; Rubido E
Ann Pharmacother; 2022 Apr; 56(4):488-493. PubMed ID: 34282650
[TBL] [Abstract][Full Text] [Related]
11. Management of dental-oral procedures in patients with hereditary angioedema due to C1 inhibitor deficiency.
Jurado-Palomo J; Muñoz-Caro JM; López-Serrano MC; Prior N; Cabañas R; Pedrosa M; Burgueño M; Caballero T
J Investig Allergol Clin Immunol; 2013; 23(1):1-6. PubMed ID: 23653967
[TBL] [Abstract][Full Text] [Related]
12. Long-term prophylaxis in hereditary angioedema management: Current practices in France and unmet needs.
Bouillet L; Fain O; Armengol G; Aubineau M; Blanchard-Delaunay C; Dalmas MC; De Moreuil C; Du Thanh A; Gobert D; Guez S; Hoarau C; Jaussaud R; Jeandel PY; Maillard H; Marmion N; Masseau A; Menetrey C; Ollivier Y; Pelletier F; Plu-Bureau G; Sailler L; Vincent D; Bouquillon B; Verdier E; Clerson P; Boccon-Gibod I; Launay D
Allergy Asthma Proc; 2022 Sep; 43(5):406-412. PubMed ID: 35868842
[No Abstract] [Full Text] [Related]
13. Androgen use in hereditary angioedema: A critical appraisal and approaches to transitioning from androgens to other therapies.
Johnston DT; Henry Li H; Craig TJ; Bernstein JA; Anderson J; Joseph K; Riedl MA
Allergy Asthma Proc; 2021 Jan; 42(1):22-29. PubMed ID: 33349293
[No Abstract] [Full Text] [Related]
14. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
Riedl M
Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
[TBL] [Abstract][Full Text] [Related]
15. Expert Review and Consensus on the Treat-to-Target Management of Hereditary Angioedema: From Scientific Evidence to Clinical Practice.
Caballero T; Lleonart-Bellfill R; Pedrosa M; Ferrer L; Guilarte M
J Investig Allergol Clin Immunol; 2023 Jul; 33(4):238-249. PubMed ID: 36811842
[TBL] [Abstract][Full Text] [Related]
16. Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries.
Guo Y; Zhang H; Lai H; Wang H; Chong-Neto HJ; Valle SOR; Zhu R
Orphanet J Rare Dis; 2022 Nov; 17(1):399. PubMed ID: 36324138
[TBL] [Abstract][Full Text] [Related]
17. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
Zuraw B; Lumry WR; Johnston DT; Aygören-Pürsün E; Banerji A; Bernstein JA; Christiansen SC; Jacobs JS; Sitz KV; Gower RG; Gagnon R; Wedner HJ; Kinaciyan T; Hakl R; Hanzlíková J; Anderson JT; McNeil DL; Fritz SB; Yang WH; Tachdjian R; Busse PJ; Craig TJ; Li HH; Farkas H; Best JM; Clemons D; Cornpropst M; Dobo SM; Iocca HA; Kargl D; Nagy E; Murray SC; Collis P; Sheridan WP; Maurer M; Riedl MA
J Allergy Clin Immunol; 2021 Jul; 148(1):164-172.e9. PubMed ID: 33098856
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis in hereditary angioedema: a United Kingdom Delphi consensus.
Yong PFK; Annals R; Diwakar L; Elkhalifa S; Gompels M; Jain R; Karim MY; Khan S; Metcalfe A; Noorani S; Steele C; Kiani-Alikhan S; Garcez T
Clin Exp Immunol; 2024 Jun; 217(1):109-116. PubMed ID: 38456386
[TBL] [Abstract][Full Text] [Related]
19. Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center.
Srinivasan C; Ritchie B; Adatia A
Front Immunol; 2024; 15():1339421. PubMed ID: 38318176
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
